Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
September 22, 2023 17:25 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small...
Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
September 06, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular...
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
August 22, 2023 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid...
Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 09, 2023 16:05 ET
|
Matinas BioPharma Holdings, Inc.
FDA indicated that approval of MAT2203 as a first-line treatment for invasive aspergillosis will require an adequately powered study with an active control group and an all-cause mortality...
Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023
August 02, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular...
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
July 26, 2023 08:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the...
Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
May 11, 2023 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid...
Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update
May 10, 2023 16:05 ET
|
Matinas BioPharma Holdings, Inc.
FDA feedback from Type B meeting reiterated the Agency’s intent to work collaboratively in advancing development of MAT2203 for the treatment of invasive fungal infections (IFIs) Phase 3 trial design...
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
May 03, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery...
Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID
April 18, 2023 08:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., April 18, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its...